Pierre-Yves Oehrli, Author at Greater Geneva Bern area - Page 47 of 55

Data protection Impressum

Pyrpose blends decentralized and regenerative finance to create a platform where consumers and businesses collaborate to reduce climate emissions.

Pyrpose’s finance platform bridges gap between consumers and climate innovators

24 October 2023

The increasing global demand for low-carbon solutions underscores the pivotal role Nanogence's smart catalyst technology is set to play in the building and construction realm.

Nanogence secures funding to propel low-carbon tech in construction

23 October 2023

Solarsplit aims to make solar energy more accessible by streamlining and enhancing the profitability of the photovoltaic panel installation process.

Solarsplit wins the top spot at the Prix BCV Innovation 2023 awards

23 October 2023

Valsynthèse’s name originates from the high-energy value of the chemical reactions involved, necessitating a special skill set for manipulation.

Valsynthèse, 40 years of innovation in the canton of Valais

23 October 2023

It’s all just overwhelming.

I need help! (Part #3 by Jimmy Jackson)

18 October 2023

The various projects and collaborations underway in Neuchâtel exemplify its commitment to harnessing solar energy for a sustainable future.

Solar technology advancements in the canton of Neuchâtel

18 October 2023

From left to right: Prof. Han (Professor of Yonsei Cancer Center), Dr. Chun (CSO of Oncosoft), Prof. Dong Wook Kim (Clinical Professor, Yonsei Cancer Center), Laura Acosta (Swiss Embassy Representative), Prof. Ik Jae Lee (Director of Heavy Ion Therapy, Yonsei Cancer Center), Dr. Christina Vallgren (CEO of Terapet), Herve Duffour (Sales and Marketing director of Terapet), Prof. Jin Sung Kim (Chief Medical Physicist of Yonsei Cancer Center & CEO of Oncosoft).

Terapet enters partnership with Korean entities for its breakthrough cancer therapy device

18 October 2023

The latest collaboration complements Vaxcyte’s strategy to commence the initial commercial launch of VAX-24, a vaccine that targets the prevention of invasive pneumococcal disease (IPD).

Lonza expands to manufacture Vaxcyte’s pneumococcal conjugate vaccine

17 October 2023

Beyond merely consolidating data, DemoSquare’s platform aims to aid companies and organizations in forecasting regulatory changes.

DemoSquare launches its AI-based platform to anticipate regulatory futures

17 October 2023

Mimix’s objective, as outlined in its strategic vision, is to introduce this wound care product to the US market by the second half of 2024.

Mimix Biotherapeutics’ breakthrough tissue regeneration treatment receives strategic investment

17 October 2023

1 … 43 44 45 46 47 48 49 50 51 … 55